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The  current  World  Health Organization  (WHO)  guidelines  on  the quality,  safety  and  efﬁcacy  of  recom-
binant  malaria  vaccines  targeting  the  pre-erythrocytic  and blood  stages  of Plasmodium  falciparum  were
adopted  by the  WHO  Expert  Committee  on  Biological  Standardization  in  2012  to  provide  guidance  on  the
quality,  nonclinical  and  clinical  aspects  of recombinant  malaria  vaccines.  A  WHO  workshop  was  orga-
nised  to facilitate  implementation  into  African  (national/regional)  regulatory  practices,  of the  regulatory
evaluation  principles  outlined  in the  guidelines  regarding  quality  aspects.  The  workshop  was used  also
to  share  knowledge  and  experience  on regulatory  topics  of chemistry,  manufacturing  and  control  with
a  focus  on vaccines  through  presentations  and an  interactive  discussion  using  a case  study  approach.
The  basic  principles  and  concepts  of  vaccine  quality  including  consistency  of production,  quality  control
and  manufacturing  process  were  presented  and  discussed  in  the  meeting.  By  reviewing  and  practicing  a
case study,  better  understanding  on  the  relationship  between  consistency  of  production  and  batch  release
tests of  an  adjuvanted  pre-erythrocytic  recombinant  malaria  vaccine  was  reached.  The  case  study  exercise
was considered  very  useful  to understand  regulatory  evaluation  principles  of vaccines  and  a  suggestion
was  made  to WHO  to  provide  such  practices  also  through  its Global  Learning  Opportunities  for  Vaccine
Quality  programme.
Crown  Copyright  © 2015  Published  by  Elsevier  Ltd. This  is  an  open  access  article  under  the CC. Introduction
Malaria has been a major public health problem and killing more
eople than any other communicable diseases except tuberculo-
is. In 2012, there approximately 207 million people contracted
alaria resulting in about 627 000 malaria deaths. The vast major-
ty of clinical cases (80%) and deaths (90%) occur in sub-Saharan
frica, with children under ﬁve years of age and primigravid
regnant women most affected [1]. There are currently no licensed
alaria vaccines though the RTS,S/AS01 is the most advanced
 Disclaimer: This report contains the collective views of an international group
f  experts, and does not necessarily represent the decisions or the stated policy of
he World Health Organization.
∗ Corresponding author. Tel.: +44 0 1707 641473; fax: +44 0 1707 641054.
E-mail address: mei.ho@nibsc.org (M.M.  Ho).
ttp://dx.doi.org/10.1016/j.vaccine.2015.06.107
264-410X/Crown Copyright © 2015 Published by Elsevier Ltd. This is an open access ar
d/4.0/).BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
candidate in clinical studies [2]. The Malaria Vaccine Technology
Roadmap has been revised in 2013 and includes a set of priority
areas in research, vaccine development, key capacities, policy and
commercialization [3]. This Roadmap’s 2015 landmark goal focuses
on a ﬁrst-generation malaria vaccine, remains unchanged; by 2015,
develop and license a ﬁrst-generation malaria vaccine that has a
protective efﬁcacy of more than 50% against severe disease and
death and lasts longer than one year [3].
The WHO  guidelines on the quality, safety and efﬁcacy of recom-
binant malaria vaccines targeting the pre-erythrocytic and blood
stages of Plasmodium falciparum were adopted by the WHO  Expert
Committee on Biological Standardization (ECBS) in 2012 [4]. This
document provides guiding principles for evaluating such vaccines
to National Regulatory Authorities (NRAs) and vaccine manufac-
turers, and also supports the pre-qualiﬁcation process of new
malaria vaccines. A one-day workshop, which was as part of the
Ninth annual meeting of the African Vaccine Regulatory Forum
ticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
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AVAREF), was organised by WHO  Headquarters to facilitate the
mplementation of the guidelines into national regulatory prac-
ices in the region. The main subject of workshop was “current
egulatory concepts and issues related to vaccine quality”. The
articipants included the representatives of NRAs of sub-Saharan
frican countries, including those where the RTS,S/AS01 vaccine
hase III or IV studies are on-going or planned, i.e. Burkina Faso,
ongo, Gabon, The Gambia, Ghana, Guinea, Kenya, Malawi, Mali,
ozambique, Nigeria, Rwanda, Senegal, South Africa, Tanzania,
ganda, Zimbabwe and Zambia. Workshop facilitators are from
HO, three WHO  Collaborating Centres on Biological Standards
Health Canada, MHRA-NIBSC and Paul-Ehrlich-Institut), Ghana
RA and GSK.
Dr. David Wood (WHO) opened the session by welcoming all
articipants and mentioned the aim of this guideline implemen-
ation workshop to support NRAs in the region who  would be
nvolved in the licensure of new malaria vaccines. He stressed the
mportance of receiving feedback from participants in terms of the
sefulness of this type of workshop in order to better tailor future
mplementation activities. Dr. Maria Baca-Estrada (Health Canada)
nd Dr. Mei  Mei  Ho (MHRA-NIBSC) were appointed chairperson
nd rapporteur of the workshop, respectively.
Dr. Hye-Na Kang (WHO) introduced the concept of WHO  guide-
ines established by ECBS in general, as well as objectives and
xpected outcomes of the workshop. She highlighted that this
ocument provides guidance to NRAs and vaccine manufacturers
n various aspects of vaccine production including quality con-
rol (QC), and characterization. WHO  assists in the implementation
f these guidelines into regulatory and manufacturers’ practices
hrough workshops at global, regional and national levels. This
orkshop was used to share experience on CMC  regulatory top-
cs with a focus on consistency of manufacturing and quality and
xamples through case study practice. As stated in the guidelines,
onsistency in production has been recognized as an essential com-
onent in the quality assurance of malaria vaccines. In particular,
RAs should carefully monitor production records and the resultsrough to post-licensure, and the key information requirement during the cycle.
of QC tests on clinical lots as well as from a series of consecutive
lots of the vaccine [4]. The expected outcomes of this workshop
were to achieve better understanding of the key principles of reg-
ulatory concepts used in the evaluation of vaccine product quality,
i.e. provide evidence of the consistency of production through prod-
uct life-cycle; and to emphasise the importance of manufacturing
process validation and control tests to ensure product quality. Fur-
thermore, this meeting also provided the opportunity to identify
better tools for facilitating implementation of the WHO  guidelines
into practices and to obtain feedback regarding the need for addi-
tional support at regional and national level.
2. Basic regulatory principles to evaluate vaccine quality
throughout product life-cycle
Dr. Maria Baca-Estrada (Health Canada) gave a comprehensive
description of the regulatory requirements throughout a product
life-cycle (Fig. 1). Product development can take many years, at this
stage thorough characterisation of a product is necessary to under-
stand the critical quality attributes of the vaccine. These studies will
enable (1) early identiﬁcation of potential problems in the manu-
facturing process, (2) identiﬁcation of assays capable of monitoring
the stability of vaccine, (3) establish critical parameters of those
lots used in clinical trials and (4) establish parameters to monitor
consistency of production. Quality control is involved throughout
the manufacturing process of a vaccine. The expectations in terms
of the quality information needed differ according to the stage
of clinical development. For Phase 1 studies, the main concern is
related to safety. Thus, emphasis is placed in ensuring the use of
validated tests to monitor product sterility, microbial contamina-
tion during production including environmental monitoring, etc.
In addition, preliminary information on quality parameters such
as potency assays, speciﬁcations and product characterization are
included as part of the clinical trial application and the expecta-
tion is that more information regarding these parameters should
be available when Phase 2 studies are conducted. By the time Phase
ine 33
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 studies are conducted, the requirements will include production
rocess validation at commercial scale, validated QC tests, product
peciﬁcations and stability data. In general, vaccine manufactur-
ng processes are complex and product characteristics are not well
eﬁned, especially for vaccines that are (1) inactivated or detox-
ﬁed, (2) of complex formulations with multiple antigens, new
djuvants and new routes of administration and (3) with the lim-
tations regarding the relevancy of non-clinical studies to predict
accine safety and efﬁcacy.
Monitoring consistency of production throughout the manufac-
uring process is the approach used to ensure the quality attributes
f the vaccine are consistent with those of the clinical lots, such
s to provide assurance that the vaccines continues to have the
xpected efﬁcacy and safety proﬁle. Vaccines are not generic prod-
cts, unlike other pharmaceuticals; therefore, the speciﬁcations are
roduct-speciﬁc and are related to the QC test used. The concept of
roduct quality has evolved to include all the stages of the manu-
acturing process, from assessing the starting materials, in-process
ontrols and ﬁnal product; thus, the monitoring the consistency
f production throughout the whole process and not limit to lot
elease. Quality control testing is carried out throughout the pro-
ess and may  involve more than 300 tests for a single lot. The
rocess is monitored by performing trend analysis of the critical
arameters.
Post-approval activities are part of the product life-cycle, and
hey include lot release, stability programme (for vaccines 1 to
 lots/year), post-approval changes, Good Manufacturing Practice
GMP) inspections and pharmacovigilance. Post-approval changes
o marketing authorization are common and the main reasons are
sually for:
implementing improvements to the manufacturing process and
new technologies;
changing manufacturing plant;
the need of scale-up of the production process;
changing the source of excipient;
changing primary container closure system, conditions of stor-
age;
expected changes due to the shelf-life of reagents, reference stan-
dards, master and/or working seed lots;
introduction or deletion of QC tests.
The WHO  guidelines for procedures and data requirements for
hanges to approved vaccines [5] were adopted by ECBS in 2014.
his document takes into account concepts of risk assessment, cur-
ent practices in some NRAs (US FDA, Health Canada, EMA  and
ustralia) and the ICH guidelines [6]. Regulatory authorities recog-
ize that any changes to the process may  impact the quality of the
accine (i.e. safety proﬁle and efﬁcacy) and any change in the infor-
ation associated with the vaccine (for example the label) may
ffect the safe use of the vaccine. Changes approved by one or more
RAs could be recognized by other NRA for the same product [5]. It
s impossible to predict every single element that can impact prod-
ct quality and their safety proﬁle. Therefore, regulatory decisions
re based on risk/beneﬁt analysis.
The regulatory oversight to ensure product quality takes into
ccount the implementation of quality systems and current GMP;
he use of scientiﬁc principles to design and evaluate manufactur-
ng processes and assays; and the use of quality risk management
ools. All these information facilitates better and more informed
ecisions and gives regulators assurance that the manufacturer has
he ability to deal with potential problems when they arise. Dr Baca-
strada concluded that the quality of a vaccine is based on several
arameters monitored throughout the product life-cycle. Vaccines
re biological products with complex manufacturing processes and (2015) 4359–4364 4361
QC testing, therefore, it is important to ensure appropriate charac-
terization, speciﬁcations and relevant assays are in place.
3. Consistency of production
Dr. Christoph Conrad (Paul-Ehrlich-Institut) presented the reg-
ulatory principles which apply to the evaluation of consistency
of production and its implications to monitor product quality.
Vaccines are very complex products when compared with other
pharmaceuticals, such as small molecule chemical drugs. In addi-
tion, their modes of action increase their complexity and their
evaluation. Biologicals are deﬁned by the manufacturing process
and appropriate testing. As stated in the WHO  guidelines for
malaria vaccine [4], QC testing during the manufacturing process
relies on the implementation of quality systems including current
GMP  to ensure consistent production of vaccine lots with the char-
acteristics similar to those lots previously shown to be safe and
effective in clinical studies. Therefore the acceptance criteria of
both drug substance and product should be established and jus-
tiﬁed based on data obtained from lots used in preclinical and/or
clinical studies; thus critical quality attributes from lots used for
demonstration of manufacturing consistency, stability studies, and
relevant development data are very important. There are three
important aspects which contribute to product consistency:
a) Control of starting and source materials: A cell bank system of
Master Cell Bank (MCB) and Working Cell Bank (WCB) should be
established and any supplier of raw material used throughout
the manufacturing process should be qualiﬁed. It is important to
ensure gene homogeneity for MCB, WCB  and End of Production
cells (EoP), as well as absence of adventitious agents throughout
the manufacturing process. Appropriate culture media should
be used and the cell banks should be maintained in a frozen
state that allows recovery without alteration of the genotype.
b) Manufacturing process: The process should be validated, and
all reagents and material should be well deﬁned. Current GMP
should be implemented to assure the consistency of the pro-
duction process including steps such as fermentation (e.g.
alteration of growth characteristics), puriﬁcation (e.g. efﬁciency
of puriﬁcation), and formulation (e.g. product homogeneity, for-
mation of aggregates or altered interactions between antigen
and adjuvants).
(c) Testing: In-process controls and quality control testing at dif-
ferent steps in the manufacturing process from single harvest,
puriﬁed antigen bulk, ﬁnal bulk through to ﬁnal lot (Table 1)
are critical elements used to monitor consistency of production;
many of these tests are captured in the summary lot protocol.
The tests performed on the ﬁnal bulk and ﬁnal lot summarizes
the quality of the product, but as outlined above, these tests alone
are not sufﬁcient to assure the quality of the product. Depending on
the production process and the characteristics of the vaccine, some
tests may  be performed on the ﬁnal bulk rather than the ﬁnal lot.
There can be a combination of different bulk batches to form a ﬁnal
lot. Referring to the guidelines on the quality, safety and efﬁcacy of
recombinant malaria vaccines targeting the pre-erythrocytic and
blood stages of P. falciparum,  formulation is generally based on pro-
tein content, but antigen content may  be used. Control tests on the
adjuvant and the evaluation of potential interactions between the
antigen and the adjuvant, should be done until consistency has been
demonstrated to the satisfaction of the NRA.To give an example of minor changes to the manufacturing
process potentially affecting the quality of the product, changes
of different supplier and/or properties of the stopper material
may  affect the quality of a product in the ﬁnal container, such as
4362 M.M. Ho et al. / Vaccine 33
Table  1
Example of typical quality control testing required at various stages of production
of  a vaccine product from single harvest to ﬁnal lot.
Production stage Control testing
Single harvest Consistency of yield (e.g. antigen content)
Testing for contamination (bacteria and fungi)
Puriﬁed antigen bulk Purity (degradation, contaminating proteins)
Antigenic activity (Protein and antigen contents)
Identity
Lipids*
Carbohydrates*
Sterility
Agents used during the puriﬁcation and other
manufacturing process*
Residuals (e.g. from the antigen expression system,
such as DNA and host proteins)*
Bacterial endotoxins
Final bulk/lot** Appearance and Identity
Sterility
General safety*
Pyrogen and endotoxin content*
Protein content
Potency
Moisture content
Inspection of containers
* Tests may be omitted after the consistency of the puriﬁcation process has been
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** Depending on the production process and the characteristics of the vaccine,
ome test may  be performed on the ﬁnal bulk rather than on the ﬁnal lot.
oisture content and chemical contaminants. The presentation of
 vaccine can be in syringe and/or vial which should be deﬁned by
n the marketing authorisation as part of the licensure application
rocess. The take home message is that ‘consistency’ is the key for
nsuring product quality even when dealing with the unknowns.
. Principles of potency tests including in vivo and in vitro
ssays
Dr Mei  Mei  Ho (MHRA-NIBSC) focussed her presentation in
otency assays. As deﬁned by WHO  potency tests measure or quan-
ify biological activities of a vaccine in comparison with a reference
reparation of known bioactivity; but do not necessarily reﬂects
he mechanism of protection in humans. Potency measurement is
ften used to verify the consistency of the manufacturing process. A
light variation as deﬁned by EMA  that potency is the quantitative
easure of biological activity, based on the attribute of the prod-
ct which is linked to the relevant biological properties. A relevant,
alidated potency assay should be part of the speciﬁcation for a
iotechnological or biological drug substance and/or drug product.
he ideal potency test from a regulatory perspective would include
he following considerations:
Able to detect clinically meaningful changes and mimic  the clin-
ically expected function of the vaccine in humans.
Based on a deﬁned biological effect as close as possible to the
mechanism(s) of action/clinical response.
Should allow a quantiﬁcation of the biological activity and
demonstrate consistency between vaccine lots.
Should be analytically validated.
The lower (efﬁcacious) or upper (safe) limits should be clinically
validated.
Should be stability indicating.
Should ensure compliance with the 3Rs principles (animal
welfare—Reﬁnement, Reduction and Replacement).The types of biological potency assays can either be in vivo or
n vitro. They can be measure quantitative and/or functional activi-
ies which may  or may  not be directly relevant for clinical activity. (2015) 4359–4364
In general, these assays make use of one or a combination of the
following approaches:
• microbiological (e.g. viral/bacteriological viability);
• biological (e.g. in vivo models, receptor-binding), immunological
(e.g., serology, cellular immunology);
• immunochemical (e.g. antigen content).
As the technology advanced, genetic approach, such as using
microarray technique, has been considered.
The leading malaria vaccine approaching licensure process is
the adjuvanted recombinant RTS,S-based vaccine. The potency test-
ing for QC release during clinical development used in vivo assays
which were based on immunogenicity in a mouse model, and com-
pared antibodies responses against either S or CS induced by test
and reference vaccine. Speciﬁcation limits were based on either
GMT  ranges or relative potency for Phase 3 clinical trials material.
This assay has been used as a potency test for QC release during
clinical evaluation of this product. Two in vitro ELISA based potency
assays have also developed by the manufacturer as part of the prod-
uct development process. A sandwich ELISA is used to detect both
Hepatitis B antigen (HBsAg) and a speciﬁc portion of the CS pro-
tein (NANP immunodominant B cell epitopes). Another inhibition
ELISA was  designed to detect HBsAg only; this assay is also used cur-
rently as an in vitro potency assay for licensed Hepatitis B vaccines.
Although there is no immune correlate of protection identiﬁed for
RTS,S adjuvanted vaccine, the antibody responses speciﬁc to NANP
repeat region have been shown to be associated with protection
in human and animal models [7–12]; possibly by neutralising the
infectivity of the P. falciparum.
A  validated in vivo or in vitro assay should be able to verify con-
sistency of production, i.e. identify vaccine batches of low potency
which may  elicit reduced immunogenicity in human; and vaccine
samples with artiﬁcially reduced potency after chemical and physi-
cal treatments. The correlation of in vivo and in vitro results has to be
established together with enhanced ability to detect vaccine degra-
dation and differentiate vaccine lots of low and high potency. If
sufﬁcient evidence of correlation is not available, the mouse in vivo
potency assay may  be required as a QC test for commercial batch
release purpose. It is important to note that potency assays are in
general designed to demonstrate consistency of production and not
necessarily as an index of clinical efﬁcacy.
Currently there is no International Standard suitable for the
standardization of assays of malaria vaccine. There are several con-
siderations for preparing and establishing a reference standard
for the RTS,S based vaccine. It should be a single batch of
lyophilised RTS,S antigen, fully characterised and evaluated in
potency tests (in vivo and in vitro), and with documented stability.
A product-speciﬁc reference preparation (usually obtained from an
established manufacturer) which is traceable to a batch of vaccine
shown to be efﬁcacious and safe in clinical trials should serve as a
reference standard which can be used in both in vivo and in vitro
potency assays. A replacement standard should be a typical batch
of vaccine of similar potency to the previous standard. For in vivo
potency assay using the mouse immunogenicity model, additional
reference controls will be required for serology, such as mouse
reference serum controls of high, medium and low titres for both
anti-CS and anti-S.
5. Validation of post-approval manufacturing change and
introduction of potency case studyDr. Marie-Chantal Uwamwezi (GSK) gave a comprehensive
presentation on vaccine manufacturing process which is com-
plex due to the nature of such products compared to other
ine 33
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harmaceutical products. It may  take 10–25 months to produce a
ingle ﬁnished product depending on the complexity of the vaccine.
ndeed, sometimes different sites (up to ﬁve) may be involved in
he manufacturing process of a vaccine requiring months of metic-
lous, rigorously planned and controlled operations. Furthermore,
accines can contain multiple components, e.g., pentavalent (DTP,
ib and HepB) vaccine, and each component can be of different
ature, such as bacterial, viral, polysaccharide, recombinant pro-
ein. Lastly, multiple steps with multiple unit operations may  be
equired throughout the manufacturing process. Nonetheless, the
uality of vaccines is built at every stage throughout the manu-
acturing process and requires strict respect of current GMP  and
he commitment to meet the needs of patients, authorities and
hareholders. QC starts at the stage of raw material reception and
hese materials undergo QC testing before being used by vaccine
anufacturer in the production process. QC ensures that all neces-
ary controls are carried out in term of purity, efﬁcacy and safety
f a product at each production step. Adherence to current GMP
ncludes facilities and equipment qualiﬁcation. Another important
spect is to have a training programme to ensure qualiﬁed person-
el is involved in manufacture and testing. The quality assurance
oncept is to ensure the quality system is adequately implemented.
Product and process robustness focusses on building knowl-
dge during development and commercial production; this will
upport the establishment of a process under control during the
ntire life of the product. As indicated in the FDA guidance 2011
13], it is important to ensure quality is controlled and appropriate
t all development steps from process design to veriﬁcation; thus
n a product lifecycle – from candidate identiﬁcation to commercial
roduct.
A large scale process is usually in place for commercial lots pro-
uction, but further scaling up may  be introduced after licensure.
fter or at the onset of Phase 3 trials, manufacturing is trans-
erred from clinical production facilities to commercial facilities.
epending on whether changes are implemented between pivotal
hase 3 trials lots and commercial lots, according to ICH Q5E, the
omparability of clinical lots to commercial lots has to be demon-
trated [14]. At commercial production stage, the control strategy
ncludes monitoring the manufacturing process performance and
dequate in-process controls as well as ﬁnal product controls. This
equires adequate characterization of critical parameters which
re subsequently trend monitored during product life-cycle. These
nclude critical process parameters as well as critical quality
ttributes.
Vaccines manufacturing and QC testing require several changes
uring life-cycle due to improvements or new technologies, the
eed for scale-up or expansion to meet demand, discontinuation of
ource materials or equipment, compliance with new regulations or
uidelines and so on. Change control have to be in place to (1) safe-
uard the quality, safety and efﬁcacy of the vaccines, (2) ensure that
uality, business, environmental, health and safety risks associated
ith the implementation of the change are assessed and managed
nd (3) ensure compliance with legal and regulatory requirements.
t also provides traceability of changes made throughout the life
ycle of a product and/or a facility. Not all changes require the
ubmission of variations to Marketing Authorization Applications
MAA) to regulatory authorities to authorize their implementation.
cientiﬁc and risk-based principles are the basis for establishing
egulatory requirements; changes to the Marketing Authorization
re evaluated on their potential impact to product quality, safety
nd efﬁcacy. The WHO  guidelines for procedures and data require-
ents for changes to approved vaccines [5] and the ICH Guideline
5E [14] provide principles for assessing the comparability of
iotechnological/biological products before and after changes are
ade in the manufacturing process for the drug substance or drug
roduct. These guidelines are intended to assist in the collection of (2015) 4359–4364 4363
relevant technical information which serves as evidence that the
manufacturing process changes will not have an adverse impact on
the quality, safety and efﬁcacy of the drug product.
Validation of an antigen bulk process change was  illustrated
as an example in the workshop. Two changes including fermenta-
tion and puriﬁcation steps were introduced. The proposed control
strategy for the case study, encompassed process control at all man-
ufacturing steps (fermentation, extraction and puriﬁcation) and
analytical tests for characterization and QC release purposes. Ana-
lytical tests are performed also at key steps during the production
process, and these are the in-process control tests.
For the case study, as changes were introduced at upstream
manufacturing steps, the validation of the revised manufacturing
process focused on the demonstration of the consistency of test
results generated during the puriﬁcation steps and on the puriﬁed
product. Data are collected to demonstrate that the puriﬁcation
steps are reproducible within and between to the previous and the
revised processes. For such validation studies of process changes,
characterization tests are also used to verify the absence of impact
on critical quality attributes such as antigenic properties, purity and
impurities proﬁle etc.
For potency testing of RTS, S-based vaccine, during clinical
development, both in vivo and in vitro potency assays were used in
parallel. The approach was  to follow the ICH Guideline Q6B [15] and
design a potency test that assesses the biophysical and immunolog-
ical characteristics of the vaccine formulation and that is valuable
as a measure of both product consistency (release) and stability
over time. For the development of an in vivo assay different mouse
strains were assessed as well as different administration routes
aiming to design a robust assay with acceptable variability. Thus the
ﬁnal selected routes were not necessarily the same as the human
administration route. The in vitro potency assays include the CS-S
ELISA and the inhibition ELISA for HBsAg as mentioned above. Mon-
itoring of consistency proved more reliable with the in vitro than
in vivo tests due to their lower variability.
6. Case study: relationship between consistency of
production and batch release tests
Dr. Eric Karikari-Boateng (Food and Drugs Board Ghana) led an
interactive discussion among participants on a case study of an
adjuvanted pre-erythrocytic recombinant malaria vaccine. Qual-
ity control potency tests for this vaccine include an in vitro ELISA
method and an in vivo immunogenicity test in mice. The objective
of the case study was  to discuss what information is required to
support the elimination of the in vivo potency test and retain the
in vitro ELISA test as potency assay for this vaccine.
The participants were divided into two groups according lan-
guage, either French or English speakers. A representative from
each group, Burkina Faso (for French speakers) and Kenya (for
English speakers) presented the outcomes of their group discus-
sion.
Preclinical proof-of-concept studies are conducted in animal
models to assess the biological function of a vaccine and to provide
a rationale to move forward with the development including the
clinical program. In many cases these animal tests are used for fur-
ther product characterization and some may  be validated for QC
testing. Once the vaccine is approved and consistency of produc-
tion established, manufacturers are likely to request the removal
of in vivo tests.
The participants discussed the pros and cons of using either in
vivo or in vitro potency assay (Table 2); and evaluated the informa-
tion provided to support the elimination of the in vivo assay taking
into account the scientiﬁc rationale provided by the manufacturer
which included evidence that the in vitro test was appropriate to
4364 M.M. Ho et al. / Vaccine 33
Table  2
The pros and cons of using either in vivo or in vitro potency assay for the RTS,S-based
vaccine for lot release purpose.
In vivo In vitro
Pros
In living animals like humans More reliable and robust and less
variable in results
Better predictor of safety signal Sensitive and better indicator for changes
Less costs and time saving
Cons
Higher variability in results Poor predictor of biological function
except if the assay uses monoclonal
antibodies targeting a deﬁned protective
epitope
Laborious and time consuming
Facilities for animal experiment
is required
Animal ethics, considerations of
3Rs
Expensive and higher costs
m
i
i
i
7
(
(
(
(
[
[
[
[
[onitor product quality and stability. Emphasis was placed on the
mportance of considering the control of the whole manufactur-
ng process as the basis of ensuring product quality, including the
mplementation of GMPs.
. Conclusion
(a) WHO  guidelines on the quality, safety and efﬁcacy of recom-
binant malaria vaccines [4] were recognized by the workshop
participants as a tool for harmonizing regulatory expectations.
b) Participants agreed that the use of case studies is an appropri-
ate tool for the implementation of WHO  regulatory standards.
It provides the opportunity to discuss and apply new informa-
tion in various contexts and taking into account the expertise
of participants. The group representatives suggested that WHO
provide such practices also through its Global Learning Oppor-
tunities for Vaccine Quality programme.
(c) Product characterization is important to ensure successful
product development by identifying problems early in the
process and ensuring key parameters of vaccine quality are
established with lots used in clinical studies.
d) Speciﬁcations should be based on characteristics of vaccine lots
demonstrated to be safe and efﬁcacious in clinical studies.
e) However, product characterization alone cannot ensure consis-
tency of production and thus the quality of the product. Product
quality is based on the whole manufacturing process, including
the control of starting material, the manufacturing process itself
(in-process controls), and ﬁnal product testing.
(f) Each vaccine is deﬁned by its manufacturing process; therefore,
product speciﬁcations should be assigned to each product based
on its clinical performance and quality characteristics.
g) Changes to the manufacturing process including quality control
testing can impact product quality. The information required
to assess these changes are based on quality risk management
[ (2015) 4359–4364
principles. Regulatory decisions are based on a risk -beneﬁt
analysis.
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